Results 231 to 240 of about 3,948,731 (294)

Fyn kinase: a key mechanistic regulator and therapeutic target in tauopathy and neurodegenerative diseases. [PDF]

Transl Neurodegener
Wang H, Fan X, Ping J, Shao Q, Wang C, Wang H, Ji Q, Su M, Qian W.   +8 more
europepmc   +1 more source

Comparative Pharmacologic Characterization of Povorcitinib (INCB054707) as a Highly Selective Oral JAK1 Inhibitor. [PDF]

Dermatol Ther (Heidelb)
Wass B, Fenix AM, Zolotarjova N, Margulis A, Zhang G, Sales D, Covington M, Santos LL, Kanellopoulou C, Macarrón R.   +9 more
europepmc   +1 more source

Myoferlin at the crossroad of vesicle trafficking and mitochondrial function: implications for pancreatic cancer progression and stromal reprogramming. [PDF]

Biochem Soc Trans
Peiffer R, Laverdeur E, Genbauffe A, Bellahcène A, Rademaker G, Peulen O.   +5 more
europepmc   +1 more source

Zidesamtinib (Jideytro®): a new selective, brain-penetrant ROS1 inhibitor approved for the treatment of ROS1-positive non-small cell lung cancer. [PDF]

Med Chem Res
Lee S, Hu L.
europepmc   +1 more source

Genome-Wide Analysis and Experimentation of Plant Serine/ Threonine/Tyrosine-Specific Protein Kinases

Plant Molecular Biology, 2006
Protein tyrosine phosphorylation plays an important role in cell growth, development and oncogenesis. No classical protein tyrosine kinase has hitherto been cloned from plants. Does protein tyrosine kinase exist in plants?
Ram Rajasekharan
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Protein tyrosine kinases and cancer

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1997
4. Tyrosine kinase activation by mutation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F222 4.1. BCR–ABL and human leukemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F222 4.2. TEL–ABL and human leukemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F224 4.3.
K S, Kolibaba, B J, Druker
openaire   +2 more sources

Inhibitors of protein tyrosine kinases

Current Opinion in Biotechnology, 1995
The description in the past year of several novel protein tyrosine kinase inhibitors, which exhibit dramatic improvements in potency and specificity over earlier agents, will be considered a major turning point in the field. These compounds appear to have the necessary pharmacological properties to finally allow clarification of whether suppression of ...
D W, Fry, A J, Bridges
openaire   +2 more sources